Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Regeneron (REGN – Research Report) and TG ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) shares reached a new 52-week low on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to ...

Rivian’s U.S. manufacturing limits its exposure to the 25% tariffs. Click here to read why I consider RIVN stock a ...

We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...

Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $130,880.12 today based ...

Biotech company Regeneron (REGN) and French pharmaceutical giant Sanofi (SNY) today announced that Japan has granted ...

We then ranked the selected stocks based on their price target upside ... If you are looking for an AI stock that is more promising than REGN but that trades at less than 5 times its earnings ...

We recently published a list of 11 Best Extremely Profitable Stocks to Buy According to Analysts. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...